Brett G Zani

20120172787, Jul 5, 2012

Jul 16, 2010

13/384216

James B. McClain - Raleigh NC, US
Charles Douglas Taylor - Franklinton NC, US
John Neet - Lawrence KS, US
Brett G. Zani - Arlington MA, US

MICELL TECHNOLOGIES, INC. - Durham NC

A61M 37/00
A61L 29/16
A61M 25/10

604 22, 60410302

Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.

20120177742, Jul 12, 2012

Dec 29, 2011

13/340472

James B. McCLAIN - Raleigh NC, US
Charles Douglas Taylor - Franklinton NC, US
Brett G. Zani - Arlington MA, US
Timothy Charles Kiorpes - Doylestown PA, US

MICELL TECHNOLOGIES, INC. - Durham NC

A61K 9/00
B05D 7/00
A61K 31/436
A61P 37/06
B82Y 5/00

424490, 424400, 514291, 427 21, 977773, 977915

Devices, coatings, and methods therefore comprise a medical device for delivering nanoparticles of an active agent to a treatment site. A coating on the medical device comprises active agent nanoparticles, which delivers coating to the treatment site and releases active agent nanoparticles into the treatment site over at least one day. A coating may comprise a polymer, a surfactant, and the nanoparticles. The coating may be prepared by forming a nanoemulsion. A coating may comprise encapsulated active agent nanoparticles which comprise active agent nanoparticles encapsulated in a polymer. The coating may have a positive surface charge. The coating may deliver active agent nanoparticles into the treatment site over at least about one day. The coating may be formed of a surfactant and nanoparticles mixture. The active agent nanoparticles may be deposited on the medical device using electrostatic capture.

20130064800, Mar 14, 2013

Aug 10, 2012

13/571494

Elazer R. Edelman - Brookline MA, US
Brett G. Zani - Arlington MA, US

Massachusetts Institute of Technology - Cambridge MA

A61K 35/12
A61P 17/02
A61P 1/00
A61P 15/00
A61P 11/00
A61P 9/00

424 937

Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair.

20130172853, Jul 4, 2013

Jul 15, 2011

13/809324

James B. McClain - Raleigh NC, US
Charles Douglas Taylor - Franklinton NC, US
Brett G. Zani - Arlington MA, US
John Neet - Lawrence KS, US
Timothy Charles Kiorpes - Doylestown PA, US

MICELL TECHNOLOGIES, INC. - Durham NC

A61M 25/10

604509, 60410302, 60410101

Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.

20100239671, Sep 23, 2010

May 6, 2008

12/738956

Elazer R. Edelman - Brookline MA, US
Brett Zani - Quincy MA, US

A61K 9/14
A61K 35/12
A61P 11/00

424484, 424 937

Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair.

20200108232, Apr 9, 2020

Dec 5, 2019

16/704024

- Durham NC, US
Charles Douglas Taylor - Franklinton NC, US
Brett G. Zani - Arlington MA, US
John Neet - Lawrence KS, US
Timothy Charles Kiorpes - Doylestown PA, US

Micell Technologies, Inc. - Durham NC

A61M 25/10
A61L 29/08
A61L 31/10
A61L 29/16
A61L 31/16

Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.

20190046695, Feb 14, 2019

Oct 15, 2018

16/160157

- Durham NC, US
Charles Douglas Taylor - Franklinton NC, US
Brett G. Zani - Arlington MA, US
John Neet - Lawrence KS, US
Timothy Charles Kiorpes - Doylestown PA, US

Micell Technologies, Inc. - Durham NC

A61L 31/08
A61M 25/10
A61B 17/12
A61L 29/08
A61L 31/16
A61L 29/16
B05D 7/24

Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until implantable device is deployed a an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.

20170367705, Dec 28, 2017

Jun 23, 2017

15/632233

- Newark DE, US
Elazer R. Edelman - Cambridge MA, US
Peter Heicksen - Flagstaff AZ, US
Theresa A. Holland - Flagstaff AZ, US
Peter M. Markham - Lexington MA, US
Peter D. Traylor - Flagstaff AZ, US
Abraham Tzafriri - Lexington MA, US
Brett G. Zani - Lexington MA, US

A61B 17/12
A61B 18/24
A61M 25/10
A61B 18/02

The present disclosure is directed toward drug coated balloons, and in particular to drug coated balloons having a microcrystalline structure and techniques for increasing vascular permeability for drug application and retention. Particular aspects may be directed to a medical device including a balloon having an outer surface, and a drug coating layer on the outer surface of the balloon. The drug coating layer includes microcrystals in a haystack orientation having random and a substantial absence of uniformity in placement and/or angle on the outer surface of the balloon.